Technical Analysis for CHRS - Coherus BioSciences, Inc.

Grade Last Price % Change Price Change
F 2.12 -2.30% -0.05
CHRS closed down 2.3 percent on Friday, May 17, 2024, on 66 percent of normal volume.
Earnings due: May 29
*** please verify all earnings dates ***
5 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Calm After Storm Range Contraction 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.30%
Calm After Storm Range Contraction -2.30%
Inside Day Range Contraction -2.30%
Crossed Above 20 DMA Bullish -2.75%
20 DMA Resistance Bearish 1.92%
Calm After Storm Range Contraction 1.92%
Gapped Down Weakness 1.92%
20 DMA Resistance Bearish 1.44%

   Recent Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Coherus BioSciences, Inc. Description

Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline consists of CHS-0214, an etanercept biosimilar candidate, which is in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420, an adalimumab biosimilar candidate that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the treatment of breast cancer patients exhibiting chemotherapy-induced neutropenia. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Immunology Breast Cancer Chemotherapy Treatment Of Breast Cancer Rheumatoid Arthritis Psoriasis Immunosuppressants Biosimilar Recombinant Proteins Adalimumab Neutropenia

Is CHRS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 5.63
52 Week Low 1.435
Average Volume 2,207,473
200-Day Moving Average 2.94
50-Day Moving Average 2.24
20-Day Moving Average 2.11
10-Day Moving Average 2.14
Average True Range 0.16
RSI (14) 48.19
ADX 15.38
+DI 14.09
-DI 22.55
Chandelier Exit (Long, 3 ATRs) 1.83
Chandelier Exit (Short, 3 ATRs) 2.30
Upper Bollinger Bands 2.32
Lower Bollinger Band 1.91
Percent B (%b) 0.52
BandWidth 19.46
MACD Line -0.03
MACD Signal Line -0.04
MACD Histogram 0.0113
Fundamentals Value
Market Cap 236.09 Million
Num Shares 111 Million
EPS -2.55
Price-to-Earnings (P/E) Ratio -0.83
Price-to-Sales 1.46
Price-to-Book 73.19
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.29
Resistance 3 (R3) 2.30 2.25 2.26
Resistance 2 (R2) 2.25 2.21 2.25 2.25
Resistance 1 (R1) 2.19 2.19 2.17 2.18 2.24
Pivot Point 2.14 2.14 2.13 2.14 2.14
Support 1 (S1) 2.08 2.10 2.06 2.07 2.00
Support 2 (S2) 2.03 2.08 2.03 1.99
Support 3 (S3) 1.97 2.03 1.98
Support 4 (S4) 1.96